✦ LIBER ✦

A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma

✍ Scribed by Sergio Ricci; Andrea Antonuzzo; Luca Galli; Carmelo Tibaldi; Maurizio Bertuccelli; Andrea Lopes Pegna; Stefano Petruzzelli; Vittorio Bonifazi; Cinzia Orlandini; Pier Franco Conte

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 88 KB
Volume: 89
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20001015)89:8<1714::aid-cncr10>3.0.co;2-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II study of paclitaxel-ifosfamid

A Phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma

✍ Christos Kosmas; Nicolas B. Tsavaris; Aristidis Polyzos; Haralambos P. Kalofonos 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

A phase II study of gemcitabine plus ora

A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Tony S. K. Mok; Benny Zee; Anthony T. C. Chan; Winnie Yeo; Wei Tse Yang; Anthony 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

UFT plus cisplatin combination chemother

UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma : A multiinstitutional Phase II trial

✍ Yukito Ichinose; Kozo Yosimori; Shuichi Yoneda; Mutsuo Kuba; Shoji Kudoh; Hisano 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

## Background: Combination chemotherapy comprised of oral uft (a combination of tegafur and uracil) and cisplatin was shown to be an effective regimen for the treatment of advanced nonsmall cell lung carcinoma and to be associated with a low incidence rate of toxicity in a previous, single institut

Increasing dose intensity of cisplatin-e

Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma : A Phase III randomized trial of the Spanish lung cancer group

✍ Albert Font; Alfredo J. Moyano; Jose M. Puerto; Alejandro Tres; Carlos Garcia-Gi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

## Background: The authors designed this randomized, controlled trial to assess whether dose intensification of a cisplatin-etoposide combination (pe), achieved by shortening the interval between chemotherapy cycles, would improve response rate and survival. the maximum tolerated dose of pe was adm

Single agent versus combination chemothe

Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma : A meta-analysis of response, toxicity, and survival

✍ Rogerio C. Lilenbaum; Patricia Langenberg; Kay Dickersin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

## Background: This meta-analysis was conducted to compare the effects of single agent versus combination chemotherapy on response rate, toxicity, and survival of patients with advanced nonsmall cell lung carcinoma (nsclc). ## Methods: The authors reviewed randomized clinical trials published in

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel